All Posts

Pharma News
ImaginAb joins hands with AstraZeneca, Pfizer, Takeda

ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the im...

Find More

HR-positive/ HER-negative Breast Cancer
HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis

Breast cancer is a serious and most common problem in developed as well as developing countries.About 1 in 8 U.S. women summing up to 12% are at the risk of developing invasive breast cancer over the course of her lifetime. And if we talk about the present scenario, there are over 3 million women in the United Stat...

Find More

Global Liver Cancer Incidence
Global Burden of Liver cancer: Is it rising? 

Liver Cancer incidence is not as high as the incidence of breast or lung cancer. However, rising diagnosis rates reveal another story. According to a survey, Liver cancer has become an increasing cause of deaths in Americans. According to the American Institute for Cancer Research, Liver cancer is the fifth most co...

Find More

First oral GLP-1 treatment approved for type2 Diabetes

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...

Find More

Osteoporosis
FDA approves Bonsity for Osteoporosis treatment

Osteoporosis, recognized as one of the most severe global burdens, is the reason behind more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds globally.FDA recently has permitted the new drug application (NDA) for Bonsity (PF708) for the treatment of osteoporosis. Submitted ...

Find More

World Pharma News
AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara

AngioDynamics, an innovative medical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo Medical. AngioDynamics is a leading player in manufacturing medical devices for vascular access, peripheral vascular disease, and oncology. The acquisition of Eximo Medical will increase the portfol...

Find More

Migraine Treatment
A New Era for Migraine Treatment and CGRP antibodies

The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. According to the Migraine Trust Organization, Migraine is ranked as the 7th most disabling disease in the world (a cause for a loss of 2.9% of all years of life lost to disability/YLDs). The ...

Find More

Peanut allergy
FDA is reviewing a dangerous way to treat Peanut Allergy

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalen...

Find More

Recent Pharma News
Roche’s Tecentriq combo proves effective in Bladder cancer

Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq, combined with Pt-based chemotherapy showed a noteworthy improvement in patients with untreated advanced bla...

Find More

Batten Disease market
Batten Disease Market: Barriers and Growth Opportunities

Batten disease overview Batten disease, referred to as Neuronal Ceroid Lipofuscinosis (NCL), is a family of rare diseases and a debilitating autosomal recessive neurodegenerative lysosomal storage disorder caused by cellular accumulation of abnormal auto-fluorescent lipoproteins lipofuscin. Patients with Batt...

Find More